Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The INFINITI Study: SGLT2 Inhibitors in Kidney Transplant Recipients
NCT04965935Phase 3Completed
- Sponsor
- University Health Network
- Start
- Jul 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in hypertension (HTN), sponsored by University Health Network. Started Jul 2021; status: completed.
02
Drugs
dapagliflozin
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04965935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965935.